For the March 2023 Global Epidemiology Conference, iWiMS featured Dr. Carmen Tur, Centre d'Escleosi Múltiple de Catalunya (Cemcat), Barcelona and Dr. Nicole Bou, Department of Neurology Johns Hopkins School of Medicine Baltimore, Baltimore.

Dr. Tur spoke about the association of early progression independent of relapse activity and long-term disability after a first demyelinating event. Dr. Bou discussed how the extended interval dosing of Ocrelizumab in patients with Multiple Sclerosis is not associated with meaningful differences in disease activity.

Please note, these videos are intended for a medical and scientific audience for educational purposes. Please acknowledge the speaker if you reference their work.